MedTrace Logo

Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant

NCT03589040 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-03-28

No results posted yet for this study

Summary

This study will evaluate the pharmacokinetic properties of rilpivirine and darunavir when used in combination with etonogestrel

Conditions

  • HIV
  • Contraception

Interventions

DRUG

Etonogestrel 68Mg Implant

Etonogestrel single-rod subdermal implant (68mg/rod) will be administered to all study participants

DRUG

rilpivirine

Oral rilpvirine 25mg

DRUG

darunavir

Oral darunavir+ritonavir 600/100mg

Sponsors & Collaborators

  • University of Nebraska

    collaborator OTHER

  • University of Pittsburgh

    collaborator OTHER

  • University of Liverpool

    collaborator OTHER

  • Makerere University

    lead OTHER

Principal Investigators

  • Mohammed Lamorde, PhD · Infectious Diseases Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-25
Primary Completion
2019-06-30
Completion
2020-06-30

Countries

  • Uganda

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03589040 on ClinicalTrials.gov